Published in Cancer Cell on May 18, 2010
The genomic complexity of primary human prostate cancer. Nature (2011) 14.06
The mutational landscape of lethal castration-resistant prostate cancer. Nature (2012) 11.82
Transcriptome sequencing across a prostate cancer cohort identifies PCAT-1, an unannotated lincRNA implicated in disease progression. Nat Biotechnol (2011) 6.54
Molecular genetics of prostate cancer: new prospects for old challenges. Genes Dev (2010) 5.83
Cell autonomous role of PTEN in regulating castration-resistant prostate cancer growth. Cancer Cell (2011) 4.43
Polycomb group proteins: multi-faceted regulators of somatic stem cells and cancer. Cell Stem Cell (2010) 4.18
Mechanistic rationale for inhibition of poly(ADP-ribose) polymerase in ETS gene fusion-positive prostate cancer. Cancer Cell (2011) 3.53
The long noncoding RNA SChLAP1 promotes aggressive prostate cancer and antagonizes the SWI/SNF complex. Nat Genet (2013) 3.39
Epigenetic modifications as therapeutic targets. Nat Biotechnol (2010) 3.16
The androgen receptor fuels prostate cancer by regulating central metabolism and biosynthesis. EMBO J (2011) 2.97
Androgen receptor gene expression in prostate cancer is directly suppressed by the androgen receptor through recruitment of lysine-specific demethylase 1. Cancer Cell (2011) 2.86
HPeak: an HMM-based algorithm for defining read-enriched regions in ChIP-Seq data. BMC Bioinformatics (2010) 2.41
The role of EZH2 in tumour progression. Br J Cancer (2011) 2.33
Identification of recurrent NAB2-STAT6 gene fusions in solitary fibrous tumor by integrative sequencing. Nat Genet (2013) 2.30
ETS factors reprogram the androgen receptor cistrome and prime prostate tumorigenesis in response to PTEN loss. Nat Med (2013) 2.26
Targeted high throughput sequencing in clinical cancer settings: formaldehyde fixed-paraffin embedded (FFPE) tumor tissues, input amount and tumor heterogeneity. BMC Med Genomics (2011) 2.24
TMPRSS2-ERG status in circulating tumor cells as a predictive biomarker of sensitivity in castration-resistant prostate cancer patients treated with abiraterone acetate. Eur Urol (2011) 2.14
ChIPBase: a database for decoding the transcriptional regulation of long non-coding RNA and microRNA genes from ChIP-Seq data. Nucleic Acids Res (2012) 2.11
A hormone-DNA repair circuit governs the response to genotoxic insult. Cancer Discov (2013) 1.97
Retinoids regulate stem cell differentiation. J Cell Physiol (2011) 1.91
Noninvasive measurement of androgen receptor signaling with a positron-emitting radiopharmaceutical that targets prostate-specific membrane antigen. Proc Natl Acad Sci U S A (2011) 1.87
ETV1 directs androgen metabolism and confers aggressive prostate cancer in targeted mice and patients. Genes Dev (2013) 1.87
Androgen receptor functions in castration-resistant prostate cancer and mechanisms of resistance to new agents targeting the androgen axis. Oncogene (2013) 1.86
Next-generation sequencing of advanced prostate cancer treated with androgen-deprivation therapy. Eur Urol (2013) 1.85
The oestrogen receptor alpha-regulated lncRNA NEAT1 is a critical modulator of prostate cancer. Nat Commun (2014) 1.84
Histone modifications predispose genome regions to breakage and translocation. Genes Dev (2015) 1.67
A comprehensive view of nuclear receptor cancer cistromes. Cancer Res (2011) 1.64
Nkx3.1 and Myc crossregulate shared target genes in mouse and human prostate tumorigenesis. J Clin Invest (2012) 1.63
Deep sequencing reveals distinct patterns of DNA methylation in prostate cancer. Genome Res (2011) 1.63
Sensitive gene fusion detection using ambiguously mapping RNA-Seq read pairs. Bioinformatics (2011) 1.58
ETV1, 4 and 5: an oncogenic subfamily of ETS transcription factors. Biochim Biophys Acta (2012) 1.58
Integration of regulatory networks by NKX3-1 promotes androgen-dependent prostate cancer survival. Mol Cell Biol (2011) 1.56
Oncogenic ETS proteins mimic activated RAS/MAPK signaling in prostate cells. Genes Dev (2011) 1.56
ERG oncogene modulates prostaglandin signaling in prostate cancer cells. Cancer Biol Ther (2011) 1.56
MYC and Prostate Cancer. Genes Cancer (2010) 1.54
Myc enforces overexpression of EZH2 in early prostatic neoplasia via transcriptional and post-transcriptional mechanisms. Oncotarget (2011) 1.52
TMPRSS2-ERG gene fusions induce prostate tumorigenesis by modulating microRNA miR-200c. Oncogene (2013) 1.51
ERG/AKR1C3/AR Constitutes a Feed-Forward Loop for AR Signaling in Prostate Cancer Cells. Clin Cancer Res (2015) 1.50
Modulation of long noncoding RNAs by risk SNPs underlying genetic predispositions to prostate cancer. Nat Genet (2016) 1.48
Cooperation between Polycomb and androgen receptor during oncogenic transformation. Genome Res (2011) 1.47
Enhancer RNAs participate in androgen receptor-driven looping that selectively enhances gene activation. Proc Natl Acad Sci U S A (2014) 1.46
Decreased FOXJ1 expression and its ciliogenesis programme in aggressive ependymoma and choroid plexus tumours. J Pathol (2016) 1.45
TMPRSS2-ERG fusion co-opts master transcription factors and activates NOTCH signaling in primary prostate cancer. Nat Genet (2017) 1.43
ROR-γ drives androgen receptor expression and represents a therapeutic target in castration-resistant prostate cancer. Nat Med (2016) 1.41
Oncogene-mediated alterations in chromatin conformation. Proc Natl Acad Sci U S A (2012) 1.40
ERG induces androgen receptor-mediated regulation of SOX9 in prostate cancer. J Clin Invest (2013) 1.38
Targeting the MLL complex in castration-resistant prostate cancer. Nat Med (2015) 1.35
Integrative functional genomics identifies an enhancer looping to the SOX9 gene disrupted by the 17q24.3 prostate cancer risk locus. Genome Res (2012) 1.35
Phospho-MED1-enhanced UBE2C locus looping drives castration-resistant prostate cancer growth. EMBO J (2011) 1.33
The tumor suppressor gene rap1GAP is silenced by miR-101-mediated EZH2 overexpression in invasive squamous cell carcinoma. Oncogene (2011) 1.32
A transcriptional repressor co-regulatory network governing androgen response in prostate cancers. EMBO J (2012) 1.32
ERG dependence distinguishes developmental control of hematopoietic stem cell maintenance from hematopoietic specification. Genes Dev (2011) 1.30
Androgen receptor-independent function of FoxA1 in prostate cancer metastasis. Cancer Res (2013) 1.26
TMPRSS2-ERG -specific transcriptional modulation is associated with prostate cancer biomarkers and TGF-β signaling. BMC Cancer (2011) 1.26
Persistent androgen receptor-mediated transcription in castration-resistant prostate cancer under androgen-deprived conditions. Nucleic Acids Res (2012) 1.24
miR-30 as a tumor suppressor connects EGF/Src signal to ERG and EMT. Oncogene (2013) 1.24
Clinical potential of the ERG oncoprotein in prostate cancer. Nat Rev Urol (2012) 1.17
Loss of PTEN is associated with aggressive behavior in ERG-positive prostate cancer. Cancer Epidemiol Biomarkers Prev (2013) 1.17
Chromatin accessibility reveals insights into androgen receptor activation and transcriptional specificity. Genome Biol (2012) 1.15
FOXP3 orchestrates H4K16 acetylation and H3K4 trimethylation for activation of multiple genes by recruiting MOF and causing displacement of PLU-1. Mol Cell (2011) 1.14
ERG cooperates with androgen receptor in regulating trefoil factor 3 in prostate cancer disease progression. Neoplasia (2010) 1.14
Antitumor activity of a pyrrole-imidazole polyamide. Proc Natl Acad Sci U S A (2013) 1.13
Membrane-anchored serine proteases in health and disease. Prog Mol Biol Transl Sci (2011) 1.13
Oncogenic activation of ERG: A predominant mechanism in prostate cancer. J Carcinog (2011) 1.13
Regulation of several androgen-induced genes through the repression of the miR-99a/let-7c/miR-125b-2 miRNA cluster in prostate cancer cells. Oncogene (2013) 1.12
Integrative genomic analyses of sporadic clear cell renal cell carcinoma define disease subtypes and potential new therapeutic targets. Cancer Res (2011) 1.12
CCN3/NOV gene expression in human prostate cancer is directly suppressed by the androgen receptor. Oncogene (2013) 1.12
Distinct ERG rearrangement prevalence in prostate cancer: higher frequency in young age and in low PSA prostate cancer. Prostate Cancer Prostatic Dis (2013) 1.11
Oncogenic ETS fusions deregulate E2F3 target genes in Ewing sarcoma and prostate cancer. Genome Res (2013) 1.11
Histone modifiers in cancer: friends or foes? Genes Cancer (2011) 1.10
PTP1B is an androgen receptor-regulated phosphatase that promotes the progression of prostate cancer. Cancer Res (2012) 1.10
Role of non-coding sequence variants in cancer. Nat Rev Genet (2016) 1.10
New strategies in prostate cancer: translating genomics into the clinic. Clin Cancer Res (2012) 1.09
Cooperativity and equilibrium with FOXA1 define the androgen receptor transcriptional program. Nat Commun (2014) 1.08
Molecular pathogenesis and progression of prostate cancer. Semin Oncol (2013) 1.08
Molecular mechanisms of ETS transcription factor-mediated tumorigenesis. Crit Rev Biochem Mol Biol (2013) 1.08
Evolution of androgen receptor targeted therapy for advanced prostate cancer. Nat Rev Clin Oncol (2014) 1.08
Androgen receptor-driven chromatin looping in prostate cancer. Trends Endocrinol Metab (2011) 1.07
YK-4-279 inhibits ERG and ETV1 mediated prostate cancer cell invasion. PLoS One (2011) 1.07
Three-tiered role of the pioneer factor GATA2 in promoting androgen-dependent gene expression in prostate cancer. Nucleic Acids Res (2014) 1.05
Ablation of the oncogenic transcription factor ERG by deubiquitinase inhibition in prostate cancer. Proc Natl Acad Sci U S A (2014) 1.04
DNA-PKcs-Mediated Transcriptional Regulation Drives Prostate Cancer Progression and Metastasis. Cancer Cell (2015) 1.04
The androgen receptor cistrome is extensively reprogrammed in human prostate tumorigenesis. Nat Genet (2015) 1.04
Prostate cancer: New answers prompt new questions regarding cell of origin. Nat Rev Urol (2010) 1.03
Molecular subtyping of primary prostate cancer reveals specific and shared target genes of different ETS rearrangements. Neoplasia (2012) 1.03
LncRNA HOTAIR enhances ER signaling and confers tamoxifen resistance in breast cancer. Oncogene (2015) 1.03
The lncRNA PCAT29 inhibits oncogenic phenotypes in prostate cancer. Mol Cancer Res (2014) 1.03
REST mediates androgen receptor actions on gene repression and predicts early recurrence of prostate cancer. Nucleic Acids Res (2013) 1.02
EZH2, an epigenetic driver of prostate cancer. Protein Cell (2013) 1.02
A role for WDR5 in integrating threonine 11 phosphorylation to lysine 4 methylation on histone H3 during androgen signaling and in prostate cancer. Mol Cell (2014) 1.02
Research resource: Genome-wide mapping of in vivo androgen receptor binding sites in mouse epididymis. Mol Endocrinol (2010) 1.01
Targeting the enhancer of zeste homologue 2 in medulloblastoma. Int J Cancer (2012) 1.01
Molecular pathways and targets in prostate cancer. Oncotarget (2014) 1.00
Sox2 is an androgen receptor-repressed gene that promotes castration-resistant prostate cancer. PLoS One (2013) 1.00
Identification of novel androgen-regulated pathways and mRNA isoforms through genome-wide exon-specific profiling of the LNCaP transcriptome. PLoS One (2011) 1.00
Mechanisms of persistent activation of the androgen receptor in CRPC: recent advances and future perspectives. World J Urol (2011) 0.99
Multifaceted role of EZH2 in breast and prostate tumorigenesis: epigenetics and beyond. Epigenetics (2013) 0.99
TMPRSS2-ERG-mediated feed-forward regulation of wild-type ERG in human prostate cancers. Cancer Res (2011) 0.99
Polycomb protein EZH2 suppresses apoptosis by silencing the proapoptotic miR-31. Cell Death Dis (2014) 0.98
Erg is a crucial regulator of endocardial-mesenchymal transformation during cardiac valve morphogenesis. Development (2012) 0.98
High-resolution profiling of histone methylations in the human genome. Cell (2007) 85.74
Genome-wide maps of chromatin state in pluripotent and lineage-committed cells. Nature (2007) 65.18
Genome-wide mapping of in vivo protein-DNA interactions. Science (2007) 64.92
Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science (2005) 39.06
Fitting a mixture model by expectation maximization to discover motifs in biopolymers. Proc Int Conf Intell Syst Mol Biol (1994) 37.96
Control of developmental regulators by Polycomb in human embryonic stem cells. Cell (2006) 28.21
Polycomb complexes repress developmental regulators in murine embryonic stem cells. Nature (2006) 25.90
The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature (2002) 18.30
An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors. Nat Genet (2008) 17.67
FoxA1 translates epigenetic signatures into enhancer-driven lineage-specific transcription. Cell (2008) 14.18
MatInspector and beyond: promoter analysis based on transcription factor binding sites. Bioinformatics (2005) 11.75
Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer. Nature (2007) 10.94
Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. J Clin Oncol (2005) 10.48
TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer. Cancer Res (2006) 7.61
Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer. Cell (2009) 7.09
A hierarchical network of transcription factors governs androgen receptor-dependent prostate cancer growth. Mol Cell (2007) 5.99
Role of the TMPRSS2-ERG gene fusion in prostate cancer. Neoplasia (2008) 5.92
Cooperativity of TMPRSS2-ERG with PI3-kinase pathway activation in prostate oncogenesis. Nat Genet (2009) 5.31
Integrative genomics analysis reveals silencing of beta-adrenergic signaling by polycomb in prostate cancer. Cancer Cell (2007) 4.43
Molecular biology of the Ets family of transcription factors. Gene (2003) 4.41
Repression of E-cadherin by the polycomb group protein EZH2 in cancer. Oncogene (2008) 3.92
A causal role for ERG in neoplastic transformation of prostate epithelium. Proc Natl Acad Sci U S A (2008) 3.83
A polycomb repression signature in metastatic prostate cancer predicts cancer outcome. Cancer Res (2007) 3.82
Interaction of murine ets-1 with GGA-binding sites establishes the ETS domain as a new DNA-binding motif. Genes Dev (1992) 3.69
Androgen receptor (AR) coregulators: a diversity of functions converging on and regulating the AR transcriptional complex. Endocr Rev (2007) 3.54
Androgen receptor gene amplification: a possible molecular mechanism for androgen deprivation therapy failure in prostate cancer. Cancer Res (1997) 3.37
Phase 1 trial of high-dose exogenous testosterone in patients with castration-resistant metastatic prostate cancer. Eur Urol (2009) 3.11
Diversity of TMPRSS2-ERG fusion transcripts in the human prostate. Oncogene (2006) 3.09
An oncogene-tumor suppressor cascade drives metastatic prostate cancer by coordinately activating Ras and nuclear factor-kappaB. Nat Med (2010) 3.09
Three-color FISH analysis of TMPRSS2/ERG fusions in prostate cancer indicates that genomic microdeletion of chromosome 21 is associated with rearrangement. Neoplasia (2006) 3.08
TMPRSS2-ERG fusion, a common genomic alteration in prostate cancer activates C-MYC and abrogates prostate epithelial differentiation. Oncogene (2008) 2.94
ETS family transcription factors collaborate with alternative signaling pathways to induce carcinoma from adult murine prostate cells. Proc Natl Acad Sci U S A (2009) 2.93
TMPRSS2:ERG fusion by translocation or interstitial deletion is highly relevant in androgen-dependent prostate cancer, but is bypassed in late-stage androgen receptor-negative prostate cancer. Cancer Res (2006) 2.83
Confirmation of the high frequency of the TMPRSS2/ERG fusion gene in prostate cancer. Genes Chromosomes Cancer (2006) 2.69
Down-regulation of human DAB2IP gene expression mediated by polycomb Ezh2 complex and histone deacetylase in prostate cancer. J Biol Chem (2005) 2.58
Ets proteins in biological control and cancer. J Cell Biochem (2004) 2.24
Pleiotropic biological activities of alternatively spliced TMPRSS2/ERG fusion gene transcripts. Cancer Res (2008) 2.18
Genomic androgen receptor-occupied regions with different functions, defined by histone acetylation, coregulators and transcriptional capacity. PLoS One (2008) 2.18
New androgen receptor genomic targets show an interaction with the ETS1 transcription factor. EMBO Rep (2007) 2.17
Role of DAB2IP in modulating epithelial-to-mesenchymal transition and prostate cancer metastasis. Proc Natl Acad Sci U S A (2010) 2.16
Progression of LNCaP prostate tumor cells during androgen deprivation: hormone-independent growth, repression of proliferation by androgen, and role for p27Kip1 in androgen-induced cell cycle arrest. Mol Endocrinol (1998) 2.06
Androgen receptor represses the neuroendocrine transdifferentiation process in prostate cancer cells. Mol Endocrinol (2003) 1.66
The role of antiandrogen monotherapy in the treatment of prostate cancer. BJU Int (2003) 1.64
ETS rearrangements and prostate cancer initiation. Nature (2009) 1.58
Induction of prostatic intraepithelial neoplasia and modulation of androgen receptor by ETS variant 1/ETS-related protein 81. Cancer Res (2009) 1.39
Extinction of E-cadherin expression in breast cancer via a dominant repression pathway acting on proximal promoter elements. Oncogene (1999) 1.35
Tumor necrosis factor-alpha represses androgen sensitivity in the LNCaP prostate cancer cell line. J Urol (2000) 1.14
Regulation of alkaline phosphatase promoter activity by forkhead transcription factor FKHR. Int J Mol Med (2002) 1.12
Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science (2005) 39.06
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature (2012) 31.78
The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature (2002) 18.30
Topological domains in mammalian genomes identified by analysis of chromatin interactions. Nature (2012) 18.23
TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Nat Cell Biol (2002) 17.41
ONCOMINE: a cancer microarray database and integrated data-mining platform. Neoplasia (2004) 17.08
Development of human protein reference database as an initial platform for approaching systems biology in humans. Genome Res (2003) 14.79
EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc Natl Acad Sci U S A (2003) 13.68
ProbeMatch: rapid alignment of oligonucleotides to genome allowing both gaps and mismatches. Bioinformatics (2009) 13.34
Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature (2009) 12.58
A comparison of phasing algorithms for trios and unrelated individuals. Am J Hum Genet (2006) 12.45
The mutational landscape of lethal castration-resistant prostate cancer. Nature (2012) 11.82
Transcriptome sequencing to detect gene fusions in cancer. Nature (2009) 11.63
Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer. Nature (2007) 10.94
Oncomine 3.0: genes, pathways, and networks in a collection of 18,000 cancer gene expression profiles. Neoplasia (2007) 10.74
Bayesian haplotype inference for multiple linked single-nucleotide polymorphisms. Am J Hum Genet (2001) 10.48
Partition-ligation-expectation-maximization algorithm for haplotype inference with single-nucleotide polymorphisms. Am J Hum Genet (2002) 10.12
TEAD mediates YAP-dependent gene induction and growth control. Genes Dev (2008) 9.88
Endocrine regulation of the fasting response by PPARalpha-mediated induction of fibroblast growth factor 21. Cell Metab (2007) 9.62
Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling. Genes Dev (2003) 9.58
Large-scale meta-analysis of cancer microarray data identifies common transcriptional profiles of neoplastic transformation and progression. Proc Natl Acad Sci U S A (2004) 9.42
Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling. Nature (2009) 9.15
Integrative molecular concept modeling of prostate cancer progression. Nat Genet (2006) 8.49
TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer. Cancer Res (2006) 7.61
Genomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancer. Science (2008) 7.59
Autoantibody signatures in prostate cancer. N Engl J Med (2005) 7.56
Meta-analysis of microarrays: interstudy validation of gene expression profiles reveals pathway dysregulation in prostate cancer. Cancer Res (2002) 7.29
Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer. Cell (2009) 7.09
p53-mediated activation of miRNA34 candidate tumor-suppressor genes. Curr Biol (2007) 6.87
An Arabidopsis thaliana T-DNA mutagenized population (GABI-Kat) for flanking sequence tag-based reverse genetics. Plant Mol Biol (2003) 6.57
Transcriptome sequencing across a prostate cancer cohort identifies PCAT-1, an unannotated lincRNA implicated in disease progression. Nat Biotechnol (2011) 6.54
The emergence of lncRNAs in cancer biology. Cancer Discov (2011) 6.32
TMPRSS2-ERG fusion prostate cancer: an early molecular event associated with invasion. Am J Surg Pathol (2007) 6.09
Recurrent gene fusions in prostate cancer. Nat Rev Cancer (2008) 6.08
Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression. Cancer Cell (2005) 6.04
A hierarchical network of transcription factors governs androgen receptor-dependent prostate cancer growth. Mol Cell (2007) 5.99
Role of the TMPRSS2-ERG gene fusion in prostate cancer. Neoplasia (2008) 5.92
Androgen-independent prostate cancer is a heterogeneous group of diseases: lessons from a rapid autopsy program. Cancer Res (2004) 5.88
Personalized oncology through integrative high-throughput sequencing: a pilot study. Sci Transl Med (2011) 5.82
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer. N Engl J Med (2015) 5.39
Chimeric transcript discovery by paired-end transcriptome sequencing. Proc Natl Acad Sci U S A (2009) 5.30